$Augmedix (AUGX.US)$ dropped from next quarter revenue guida...

$Augmedix (AUGX.US)$ dropped from next quarter revenue guidance decrease in quarterly report. Looks like a buy as company expects the change from Live medical documentation review to AI documentation review to be positive in long run, transition to a SaaS company. Waiting to see the bottom and then potentially going in once Ive got cash back from $Scorpius Holdings (SCPX.US)$ swing trade